Pipeline-building biotech with game-changing antibody platform

Oblique Therapeutics is a curiosity-driven, innovative biotech company with strong scientific acumen and drive for increasing the bandwidth of antibody therapeutics, focusing on pain and aggressive-metastatic cancer.

Introducing the pioneering AbiprotTM technology

We have a solid portfolio of promising future medicines and proprietary AbiprotTM technology, our evergreen antibody platform that can generate functional antibodies to any given disease-modifying target.

We are focusing on finding new treatment paradigms for severe diseases such as aggressive metastatic cancer and pain. We also work on two type 2 diabetes programs through a collaboration with big pharma.

Learn more

Find out more about our portfolio

Oblique Therapeutics currently has eleven programs in the pipeline with a focus on pain and aggressive-metastatic cancer.

Four current programs are being developed in collaboration with leading pharmaceutical companies.

Learn More